NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/05/2025
Back to search
Official data from USPTO
EPITOPEA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EPITOPEA
ST13
US500000098426932Class
1, 5, 35, 42
Filing
98426932
Registration
7877770
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
08/05/2025
Trademark type
Word
Nice classes
1, 5, 35, 42
Filing date
02/29/2024
Registration date
08/05/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/05/2025
Last transaction
08/05/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
16
Owner location
Cambridge, GB
Examiner
DEFORD, JEFFREY S
Law office
M60
Current location
INTENT TO USE SECTION
Holders and representatives
Holders
Epitopea Limited
Representatives
Scott D. Locke Dorf Nelson & Zauderer LLP
Technical classification
Nice Classes
Class 1Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Cells for scientific or research purposes; chemical substances for use in the manufacture of medicinal and pharmaceutical products; Chemicalsreagents and substances for medical research purposes; Immunoassay reagentsother than for medical or veterinary use; Chemicals for use in immuno-assay testing other than for medical or veterinary use; Immunoassays based on polypeptides for determining immunological profileother than for medical or veterinary use; Diagnostic preparations and reagents for scientific or research use; Test kits consisting primarily of peptidesnucleic acidsbuffersreagents for scientific or research use; Nucleic recombinant acids other than for medical or veterinary purposes; Nucleic acid sequencing programsother than for medical or veterinary use; Chemical reagents for use in oncology research; Reagents for medical research; Diagnostic reagentsother than for medical or veterinary use; Cell culture reagents for scientific and research use; Biological preparations for use in cell cultures other than for medical or veterinary use; Substances for use in genetic probe assay kitsother than for medical or veterinary use; Antibodies for scientific purposes
Class 5
Pharmaceuticalmedical or veterinary preparations and substances for the treatment of cancer and diseases of the immune system; Pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; Compounds for treating cancer; Biopharmaceuticals for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer and diseases of the immune system for use in the fields of medicinehealthoncologyimmunology; biological compounds or preparations for the treatment of cancer and diseases of the immune system; biological compounds or preparations for the prevention of cancer and diseases of the immune system; Therapeutic preparations for cancer and diseases of the immune system; Genetic markers for therapeutic or diagnostic use; Cells for medical use; pharmaceutical preparations for the prevention or treatment of tumors; Pharmaceutical preparations for activating cellular function; Cell growth media for growing cells for medical use; Cellular function activating agents for medical purposes; Reconstituted cells for medical treatments; Preparations for detecting genetic predispositions for medical purposes; Pharmaceutical preparations for the prevention or treatment of immune system related diseases and disorders; Immunomodulators; Immunostimulants; Pharmaceutical preparations for immunity adjustment; Immunoassay reagents for medical use; Immunotherapeutic agents for use in treating bacterial infections; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Vaccines; Tumor antigens for medical use; antigens for medical use; viral antigens for medical use; endogenous antigens for medical use; exogenous antigens for medical use; Biological compounds for use in the targeted pharmaceutical therapies; Proteins with diagnostic and therapeutic uses for medical use; Proteins for medical use; Diagnostic reagents for medical use; Reagents and substances for use in testing for medical purposes; Diagnostic and testing preparations for clinicalmedical and medical laboratory use; Diagnostic and testing apparatus in the field of modulating therapeutics; Biomarkers for medical use; Nucleic acid sequences for medical purposes; Nucleic recombinant acids for medical use; Biological preparations and biological compounds for the treatment of cancer and diseases of the immune system; Biological reagents for medical use; Biological tissue cultures for medical purposes; Indicators for medical diagnosis; In vivo diagnostic scanning agents for medical use; Diagnostic agents for pharmaceutical or medical use; Diagnostic biomarker reagents for medical purposes; diagnostic test kits consisting primarily of peptidesnucleic acidsbuffersreagentsfor medical purposes; Medical diagnostic test strips for use in the field of cancer and diseases of the immune system; Pharmaceutical preparations for the treatment of cancers
Class 35
Compilation of statistical data relating to medical research for business purposes; Database management; Data processing; Data processingsystematization and management; Data processing services in the field of healthcare; Promoting public awareness of diseasesavailable medical treatments and disease prevention practices; Promoting public awareness of medical conditionsdiagnosis of medical conditions and prevention of medical conditions; Consultancy and advisory services relating to all of the aforesaid services
Class 42
Scientific research for medical purposes in the area of cancerous diseases; Research and development in the fields of oncologyimmunology; Research and development services in the fields of oncology and immunology research and development; Drug discovery; drug development; Medical and scientific researchconducting clinical trials for others; Research relating to genetics; Research and development in the field of therapeutics; Research and development in the fields of biotechnologypharmaceuticalsdiagnostic preparationsvaccinesmedicinesmolecular sciencesclinical trials and therapeutics; Scientific laboratory services; Laboratory testing and analysis of materials; Biological research laboratory services; Services of a chemical laboratory; Development of biochemical reagents; Research and development of biological drug delivery platforms; Development of computer softwarecomputing methods and algorithms; Computer programming; Database design; Online database maintenance for others; Design and development of computer software for use with medical technology; Design and development of software for medical diagnostic or veterinary diagnostic purposes; Design and development of computer systems for data inputoutputprocessingdisplay and storage; technical surveying; Analysis of technical dataoncology and immunology data; Research relating to data processing; Provision of research information and data relating to medical and veterinary research and development; Scientific research in the field of oncology and immunology conducted using databases; Consultancyinformation and advisory services relating to all of the aforesaid services
Publications
History of USPTO decisions and trademark events.
20 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/05/2025
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
07/16/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/16/2025
IUCN
NOTICE OF ALLOWANCE CANCELLED
02/05/2025
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
02/05/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2024
PUBO
PUBLISHED FOR OPPOSITION
12/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/04/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/07/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/07/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/17/2024
GNRT
NON-FINAL ACTION E-MAILED
09/17/2024
CNRT
NON-FINAL ACTION WRITTEN
09/17/2024
DOCK
ASSIGNED TO EXAMINER
09/17/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/11/2024
NWAP
NEW APPLICATION ENTERED
02/29/2024
Continuous trademark protection
Get notified about every new filing that threatens EPITOPEA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.